Natco’s settlement of patent case with Gilead covering 30 mg, 45 mg and 75 mg versions of Tamiflu

Natco Pharma Ltd and its partner Alvogen Inc. have settled a patent infringement case with US drug maker Gilead Sciences Inc., and Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd and Genentech Inc., thus clearing the way into the world’s largest pharmaceutical market for the Indian drug maker in terms of launching generic versions of anti-influenza drug, Tamiflu [more].